UnknownPhase 3

The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients

Indonesia66 participantsStarted 2019-06-27

Plain-language summary

Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease. We hypothesized that we hypothesized that ramipril will improve rheumatic mitral valve fibrosis through the downregulation of ST2.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients with congenital heart disease
✕. patients with non-mitral valve surgery
✕. patients with coronary artery bypass surgery
✕. patients who refuse to join this study.
✕. adults aged over 65 years or older
✕. pregnant women
✕. patients with autoimmune disease.
✕. Patients with persistent hypotension (systolic blood pressure (BP) \< 100 mm Hg)

What they're measuring

ST2 expression in mitral valve tissue and papillary muscle

Timeframe: a year

Trial details

NCT IDNCT03991910

SponsorIndonesia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-08

Contact for this trial

Ade Meidian Ambari, MD, FIHA

021-5684085 dr_ade_meidian@yahoo.co.id

View on ClinicalTrials.gov More Rheumatic Heart Disease trials